Terms: = Cervical cancer AND FOXL2, BPES, 668, ENSG00000183770, P58012, PFRK, POF3, PINTO, BPES1 AND Prognosis
4 results:
1. Combined dynamic contrast enhanced MRI parameter with clinical factors predict the survival of concurrent chemo-radiotherapy in patients with 2018 FIGO IIICr stage cervical cancer.
Qin F; Pang H; Ma J; Zhao M; Jiang X; Tong R; Yu T; Luo Y; Dong Y
Eur J Radiol; 2021 Aug; 141():109787. PubMed ID: 34051683
[TBL] [Abstract] [Full Text] [Related]
2. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in cervical cancer.
Prabawa IPY; Bhargah A; Liwang F; Tandio DA; Tandio AL; Lestari AAW; Budiana ING; Manuaba IBAP
Asian Pac J Cancer Prev; 2019 Mar; 20(3):863-868. PubMed ID: 30912405
[TBL] [Abstract] [Full Text] [Related]
3. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Spaans VM; Trietsch MD; Crobach S; Stelloo E; Kremer D; Osse EM; Haar NT; van Eijk R; Muller S; van Wezel T; Trimbos JB; Bosse T; Smit VT; Fleuren GJ
PLoS One; 2014; 9(3):e93451. PubMed ID: 24671188
[TBL] [Abstract] [Full Text] [Related]
4. Mutant p53 protein in the serum of patients with cervical carcinoma: correlation with the level of serum epidermal growth factor receptor and prognostic significance.
Oh MJ; Choi JH; Lee YH; Lee JK; Hur JY; Park YK; Lee KW; Chough SY; Saw HS
Cancer Lett; 2004 Jan; 203(1):107-12. PubMed ID: 14670624
[TBL] [Abstract] [Full Text] [Related]
